Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a clinical trial of AP-188 in acute ischemic stroke patients

Next Previous
X
Search
Trial Profile

Phase 2a clinical trial of AP-188 in acute ischemic stroke patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs N-N-dimethyltryptamine (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms STROKE Study
  • Sponsors Algernon Pharmaceuticals

    • Most Recent Events

    • 24 Apr 2024 According to an Algernon Pharmaceuticals media release, company plans to begin a Phase 2a clinical trial in acute ischemic stroke patients in 2024.
    • 08 Aug 2023 According to an Algernon Pharmaceuticals media release, the decision to advance into a Phase 2 study was based on positive data from the Company's Phase 1 trial conducted at the Centre for Human Drug Research (CHDR) in Leiden, Netherlands.
    • 17 Jan 2023 According to an Algernon Pharmaceuticals media release, the trial is expected to begin by the end of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top